Centre for Nano and Soft Matter Sciences - Official

The Centre for Nano and Soft Matter Sciences (CeNS) is an autonomous research institute under the Department of Science and Technology (DST), Government of India. DST provides core support to the Centre in the form of a grant-in-aid for conducting basic and applied research in nano and soft matter sciences. CeNS is located in its new campus, 'Arkavathi' at Shivanapura, Bengaluru North, which hosts ample greenery and has a lovely serene space that would inspire new ideas and probably lead to path-breaking scientific achievements. The Centre is engaged in materials research at all relevant length scales. Specifically, the current activities are focused on a variety of metal and semiconductor nanostructures, liquid crystals, gels, membranes and hybrid materials. It has close interactions with many Institutions and Industry, in India and abroad. The Centre was established in 1991 by an eminent liquid crystal scientist, Prof. S. Chandrasekhar, FRS. It was then known as Centre for Liquid Crystal Research, a registered scientific society in Karnataka with the objective to build a centre of excellence in line with the international trend those days on liquid crystal materials and devices. In 1995, it became an autonomous institute under the Department of Electronics (DOE), Government of India and in 2003, was brought under DST. Subsequently in the year 2010, the name was changed to Centre for Soft Matter Research. Recently in 2014, the Centre has further widened the scope of research activities to embrace nanoscience and technology and is now known as Centre for Nano and Soft Matter Sciences (CeNS). It is being mentored by Nano-Mission of the Government of India.

Gentronix Limited

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.

Shivam Technologies

Shivam Technologies is a Technology Solutions Provider based in Australia with offices in Singapore and India. Shivam provides customised IT solutions, website design and Internet marketing services. The solution includes IT consultancy, custom software development, onsite/offsite services, web development, software and web application testing and enterprise architecture consulting. It is positioned to deliver rapid, reliable and robust information technology solution that work. Shivam has shown consistent record of dynamic growth since its inception in 2001 and enjoys trust and value of its clients. The company is focused on providing solutions to its clients using Microsoft.Net technologies. Shivam is a technology intensive corporation geared to deliver state-of-the-art solutions in areas of integrated business solutions, system applications, product development, Internet/Intranet applications and communication & network management services. Shivam Offices are located in Melbourne and Brisbane Australia, Ahmedabad India and Singapore. Shivam employees are highly qualified and experienced, more than 50% of our employees are engineers and more than 20% of them have post graduate degrees in areas like technology and science.

Circadian Technologies Limited

Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company focused on the development of biologics-based therapies for the treatment of cancer and eye disease. Circadian owns an extensive patent portfolio covering targets (VEGF-C, VEGF-D, VEGFR-3) and drugs (VGX-100 and VGX-300) to modulate the processes of angiogenesis - the development of blood vessels within the body and lymphagiogenesis-the development of lymphatics in the human body. Circadian's product pipeline includes biologics drugs targeting important mediators of angiogenesis and lymphangiogenesis. Circadian's lead development candidate, VGX-100, is a fully human antibody that inhibits the VEGF-C protein. VGX-100 is currently in Phase 1a and Phase 1b clinical trials in late stage cancer patients at 2 leading US cancer centres. These studies are being done under an IND. Phase 2 studies are expected to commence in H2 2013. VGX-100 and VGX-300 are also being developed as agents to treat age related macular degeneration in patients non-responsive to anti-VEGF-A therapy. VEGF-C and VEGFR-3 have been shown to play a major role in retinal angiogenesis. VGX-100 and VGX-300 have been shown to be effective in animal models of back of the eye disease. They are currently in pre-clinical development with clinical development expected to commence by H1 2014.

Victorian Centre for Sustainable Chemical Manufacturing - VCSCM

We help Australian industry improve competitiveness and capability through research and development of sustainable chemical products and processes. To do this, we connect industry with training, knowledge and innovations in Green Chemistry and Engineering. The Victorian Centre for Sustainable Chemicals Manufacturing (VCSCM) is a consortium of the State Government of Victoria, EPA Victoria, Plastics and Chemicals Industry Association (PACIA), Commonwealth Scientific and Industrial Research Organisation (CSIRO) and Monash University.